Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome

Edmund C. Jenkins, Lingling Ye, Sharon J. Krinsky-Mchale, Warren B. Zigman, Nicole Schupf, Wayne P. Silverman

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Previous studies have suggested that Alzheimer's disease (AD) causes an accelerated shortening of telomeres, the ends of chromosomes consisting of highly conserved TTAGGG repeats that, because of unidirectional 5′-3′ DNA synthesis, lose end point material with each cell division. Our own previous work suggested that telomere length of T-lymphocytes might be a remarkably accurate biomarker for "mild cognitive impairment" in adults with Down syndrome (MCI-DS), a population at dramatically high risk for AD. To verify that the progression of cognitive and functional losses due to AD produced this observed telomere shortening, we have now examined sequential changes in telomere length in five individuals with Down syndrome (3F, 2M) as they transitioned from preclinical AD to MCI-DS (N=4) or dementia (N=1). As in our previous studies, we used PNA (peptide nucleic acid) probes for telomeres and the chromosome 2 centromere (as an "internal standard" expected to be unaffected by aging or dementia status), with samples from the same individuals now collected prior to and following development of MCI-DS or dementia. Consistent shortening of telomere length was observed over time. Further comparisons with our previous cross-sectional findings indicated that telomere lengths prior to clinical decline were similar to those of other adults with Down syndrome (DS) who have not experienced clinical decline while telomere lengths following transition to MCI-DS or dementia in the current study were comparable to those of other adults with DS who have developed MCI-DS or dementia. Taken together, findings indicate that telomere length has significant promise as a biomarker of clinical progression of AD for adults with DS, and further longitudinal studies of a larger sample of individuals with DS are clearly warranted to validate these findings and determine if and how factors affecting AD risk also influence these measures of telomere length.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume171
Issue number2
DOIs
StatePublished - Mar 1 2016

Keywords

  • Biomarker
  • Dementia status
  • Down syndrome
  • FISH with PNA (peptide nucleic acid) probes
  • Mild cognitive impairment (MCI)
  • Telomere length in light intensity units
  • Telomere length in microns
  • Telomere longitudinal shortening

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome'. Together they form a unique fingerprint.

Cite this